title: Repeated immunization with recombinant gp160 human immunodeficiency virus (HIV) envelope protein in early HIV-1 infection: evaluation of the T cell proliferative response.
abstract: This longitudinal study was designed to evaluate cellular immunity in early-stage, asymptomatic human immunodeficiency virus (HIV)-1-infected persons (CD4 cell count,>400/mm3; median, 625/mm3) who were immunized with either recombinant (r) gp160 or placebo every 2 months for 5 years. Proliferative responses were assessed against rgp160, rp24, and a panel of recall antigens and mitogens. Despite good reactivity to recall antigens, at baseline approximately 33% had proliferative responses to gp160, and approximately 42% showed p24 gag responses. There was no statistical difference between vaccine and placebo groups for antigens or mitogens. After 1 year, approximately 73% of the subjects in the vaccine arm had new or boosted responses to gp160, versus approximately 18% in the placebo arm. Statistical significance was maintained throughout the study. Recurrent vaccination with recombinant gp160 was proven to be persistently immunogenic, increasing significantly the ability of HIV-1-infected persons to mount new proliferative responses to the vaccine.
authors.affiliation: Henry M. Jackson Foundation, Rockville, MD 20850, USA. skim@hiv.hjf. org
authors.forename: S
authors.initials: S
authors.lastname: Ratto-Kim
authors.forename: K V
authors.initials: KV
authors.lastname: Sitz
authors.forename: R P
authors.initials: RP
authors.lastname: Garner
authors.forename: J H
authors.initials: JH
authors.lastname: Kim
authors.forename: C
authors.initials: C
authors.lastname: Davis
authors.forename: N
authors.initials: N
authors.lastname: Aronson
authors.forename: N
authors.initials: N
authors.lastname: Ruiz
authors.forename: K
authors.initials: K
authors.lastname: Tencer
authors.forename: R R
authors.initials: RR
authors.lastname: Redfield
authors.forename: D L
authors.initials: DL
authors.lastname: Birx
mesh_terms: D016915:AIDS Vaccines / Q000008:administration & dosage / Q000276:immunology*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015925:Cryopreservation; D004311:Double-Blind Method; D005500:Follow-Up Studies; D019302:HIV Envelope Protein gp160 / Q000008:administration & dosage / Q000276:immunology*; D015658:HIV Infections / Q000276:immunology / Q000628:therapy*; D006801:Humans; D007114:Immunization; D007963:Leukocytes, Mononuclear / Q000276:immunology; D008137:Longitudinal Studies; D008213:Lymphocyte Activation; D008875:Middle Aged; D008934:Mitogens / Q000276:immunology; D016176:T-Lymphocyte Subsets / Q000276:immunology*; D014614:Vaccines, Synthetic / Q000008:administration & dosage / Q000276:immunology
chemical_list: D016915:AIDS Vaccines; D019302:HIV Envelope Protein gp160; D008934:Mitogens; D014614:Vaccines, Synthetic